Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 11INDUSTRY 3NIH 1NETWORK 1FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other 1Head & Neck 1

Conditions

Neoplasms 2870Carcinoma, Non-Small-Cell Lung 2420Breast Neoplasms 2065Colorectal Neoplasms 1239Neoplasm Metastasis 1223Prostatic Neoplasms 1076Melanoma 972Multiple Myeloma 960Ovarian Neoplasms 899Recurrence 849Leukemia, Myeloid, Acute 807Lung Neoplasms 756Pancreatic Neoplasms 750Lymphoma, Non-Hodgkin 726Lymphoma 660Stomach Neoplasms 622Carcinoma, Hepatocellular 564Carcinoma, Renal Cell 544Squamous Cell Carcinoma of Head and Neck 525Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 449Glioblastoma 435Advanced Solid Tumors 430Small Cell Lung Carcinoma 408Triple Negative Breast Neoplasms 407Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 367Advanced Solid Tumor 349

Interventions

tempol 1sodium thiosulfate 1ebselen 1Sodium Chloride 1Hyaluronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Ototoxicity × Clear all
NCT03480971 2024-11-20

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Matrix Biomed, Inc.

Phase 2 Recruiting
120 enrolled
Other

Ototoxicity, Mucositis

NCT04262336 2023-07-06

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

Decibel Therapeutics

Phase 1 Completed
22 enrolled

Ototoxicity, Hearing Loss

NCT01451853 2017-09-25

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Unknown
80 enrolled
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡